Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trialGilbert Bensimon, Massimo Locati, P. Nigel Leigh et al.|The Lancet|2025Cited by 33
Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UKRebecca L. Gould, Jessica Marsh, Matthew Bursnall et al.|The Lancet|2024Cited by 30